Esomeprazole for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs

ClinicalTrials.gov ID: NCT00241540

Public ClinicalTrials.gov record NCT00241540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo & Esomeprazole 20 mg Once Daily Versus Placebo in Treatment for Relief of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study is a randomised, double-blind, parallel-group and placebo controlled study comparing the efficacy of esomeprazole 40 mg orally qd vs. placebo and esomeprazole 20 mg orally qd vs. placebo when given to patients on continuous use of NSAIDs, including COX-2 selective NSAIDs, for a period of 4 weeks in treatment of relief of upper GI symptoms.

Study identification

NCT ID: NCT00241540
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 808 participants

Conditions and interventions

Conditions

GERD

Interventions

Esomeprazole Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2001 (Type not available)
Primary completion: Aug 2002 (Actual)
Completion: Aug 2002 (Actual)
Last update posted: Jan 24, 2011

2001 – 2002

United States locations

U.S. sites: 19
U.S. states: 10
U.S. cities: 19

Facility	City	State	ZIP	Site status
Research Site	Tucson	Arizona	—	—
Research Site	Anaheim	California	—	—
Research Site	Orange	California	—	—
Research Site	San Francisco	California	—	—
Research Site	Bradenton	Florida	—	—
Research Site	Clearwater	Florida	—	—
Research Site	Fort Lauderdale	Florida	—	—
Research Site	Jacksonville	Florida	—	—
Research Site	South Miami	Florida	—	—
Research Site	West Palm Beach	Florida	—	—
Research Site	Zephyrhills	Florida	—	—
Research Site	Conyers	Georgia	—	—
Research Site	Newburgh	Indiana	—	—
Research Site	Baltimore	Maryland	—	—
Research Site	Winston-Salem	North Carolina	—	—
Research Site	Tulsa	Oklahoma	—	—
Research Site	Tipton	Pennsylvania	—	—
Research Site	Norfolk	Virginia	—	—
Research Site	Virginia Beach	Virginia	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 100 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00241540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 24, 2011 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00241540 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →